by CheckRare Staff | Oct 28, 2026
In this episode, we discuss gambling on clinical trials, the FDA approval of a new formulation of Sjögren’s disease treatment, and an approval in IgA nephropathy. FDA Approves a New Liquid Formulation for Sjögren’s Disease The FDA has approved a...
by CheckRare Staff | Oct 28, 2026
In this episode, endocrinologist Margarita Ochoa-Maya, MD, speaks with NIH endocrinologist Katherine Araque, MD, about clinical trials for rare endocrine disorders. The conversation examines clinical trials from three perspectives: patients, clinical researchers, and...
by CheckRare Staff | Oct 21, 2026
On this episode, we discuss the FDA approval of Enspryng for TED, the new FDA Rare Disease Framework Initiative, Ultrangenyx’s second sold PRV this month, and using AI to reduce diagnostic delays. FDA Approves Treatment for TED The FDA has approved...
by CheckRare Staff and Ailene Cantelmi | Oct 14, 2026
In this episode, we discuss Ultragenyx’s Priority Review Voucher that sold for $210 million, the efficacy of newborn screening on MLD, and ethical considerations needed to design and conduct clinical trials. Ultragenyx sells PRV for $210M This past week,...
by CheckRare Staff and Ailene Cantelmi | Oct 12, 2026
Jorge Nieva, MD, Associate Professor at the Keck School of Medicine, discusses new analyses from the TRUST studies evaluating taletrectinib in patients with ROS1-positive non-small cell lung cancer (NSCLC). ROS1-positive NSCLC is a rare molecular subtype of...